

Supplementary Material

Toll-like receptor 2 release by macrophages: an anti-inflammatory program induced by glucocorticoids and lipopolysaccharide

Jessica Hoppstädter^{1*}, Anna Dembek¹, Rebecca Linnenberger¹, Charlotte Dahlem¹, Ahmad Barghash², Claudia Fecher-Trost³, Gregor Fuhrmann⁴, Marcus Koch⁵, Annette Kraegeloh⁵, Hanno Huwer⁶, Alexandra K. Kiemer^{1*}

¹Department of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany

²Department of Computer Science, German Jordanian University, Amman, Jordan

³Department of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Homburg/Saar, Germany

⁴Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany


⁵INM – Leibniz Institute for New Materials, Saarbrücken, Germany

⁶Department of Cardiothoracic Surgery, Völklingen Heart Centre, Völklingen, Germany


*Corresponding authors:

j.hoppstaedter@mx.uni-saarland.de, pharm.bio.kiemer@mx.uni-saarland.de


Supplementary Figures




Supplementary Figure 1. *Treatment schemes and serum deprivation do not impair cell viability.* A, B: Caspase-3-like activity assay. Cells were treated with the vehicle control (0.1% DMSO, Co), LPS (100 ng/mL), Dex (1 μ M), or LPS + Dex for 3 d in serum-free medium. Treatment with 10 μ M doxorubicin (Doxo) for 24 h served as a positive control. An increase in apoptosis-associated caspase-3-like activity was neither detected in THP-1 cells (A) nor in AMs (B) (n = 3). C: Zombie yellow viability staining. Differentiated THP-1 cells were cultured in in serum-containing (+ FCS) or serum-free (- FCS) medium for 3 d. Cells incubated at 60°C for 1 h (heat) served as a positive control. Cell viability was not affected by serum-free medium (n = 2, triplicates).




Supplementary Figure 2. *Gradient for nano-liquid chromatography.* Time points for changes in buffer B concentrations are given in the table.



Supplementary Figure 3: ADAM10 and ADAM17 expression in AMs. AMs were treated with vehicle (Co) or LPS (100 ng/ml) + Dex (1 μ M) for 24 h. ADAM10 and ADAM17 expression was determined by qPCR, and values were normalized to the housekeeping gene ACTB. The means of 3 experiments performed in triplicate + SEM are shown. ***p < 0.001. p-values were generated by ANOVA with Bonferroni's post-hoc test.



Supplementary Figure 4: Correlation between EV concentration and protein amount. EVs were isolated from THP-1 macrophages treated with the vehicle control (0.1% DMSO, Co), LPS (100 ng/mL), Dex (1 μ M) or LPS + Dex for 3 d in serum-free medium. Values for seven individual isolations are given. $\blacksquare = Co$, $\bullet = LPS$, $\blacktriangle = Dex$ and $\bullet = LPS+Dex$.



Supplementary Figure 5: *Influence of dexamethasone and LPS on* DUSP1 *expression and p38 MAPK activation.* AMs were preincubated with the GR inhibitor RU486 (10 μ M) or solvent control (0.1% EtOH) and treated with LPS (100 ng/mL), Dex (1 μ M), or both for 24 h. A: *DUSP1* expression was measured by qPCR. B, C: Phospho-p38 and total p38 were analyzed by Western Blot. Tubulin served as a loading control. Data from at least three independent experiments performed in duplicate with cells from different donors are presented as means + SEM and A, C: *p < 0.05, **p < 0.01. ***p < 0.001. C: #p < 0.05 vs. vehicle-treated Co. p-values were generated by ANOVA with Bonferroni's post-hoc test.

Supplementary Tables

Supplementary Table 1: PCR conditions.

Gene	Sequence (5'→3') forward primer	Sequence (5'→3') reverse primer	Probe sequence (5'FAM→3'BHQ)	Probe [nM]	MgCl2 [mM]	Annealing [°C]
ACTB	TGCGTGACA TTAAGGAGA AG	GTCAGGCAG CTCGTAGCT CT	CACGGCTGCTTC CAGCTCCTC	60	4	60
ADAM10	TGCCCAGAT ATCCAGTCA TGTT	TCACCATGA AACTGATGT TACGG	no probe	N/A	N/A	60
ADAM17	AGAGAACCA CCTGAAGAG CTTG	TCCCCTCTG CCCATGTAT CT	no probe	N/A	N/A	60
CCL2	TTGATGTTT TAAGTTTAT CTTTCATGG	CAGGGGTAG AACTGTGGT TCA	no probe	N/A	N/A	60
CXCL10	GAGCCTACA GCAGAGGAA CC	AAGGCAGCA AATCAGAAT CG	TCCAGTCTCAGC ACCATGAATCAAA	60	4	60
DUSP1	CAGCTGCTG CAGTTTGAG TC	AGGTAGCTC AGCGCACTG TT	no probe	N/A	N/A	64
FPR2	GCATCCTCA GGAAAATGC ACC	GCATCCTCA GGAAAATGC ACC	no probe	N/A	N/A	60
ICAM	GAAGTGGCC CTCCATAGA CA	TCAAGGGTT GGGGTCAGT AG	no probe	N/A	N/A	60
IL10	CAACAGAAG CTTCCATTC CA	AGCAGTTAG GAAGCCCCA AG	AGCCTGACCACG CTTTCTAGCTGTTGA G	100	4	60

MMP9	CTTTGAGTC CGGTGGACG AT	TCGCCAGTA CTTCCCATC CT	no probe	N/A	N/A	60
SELE	AGCCCAGAG CCTTCAGTG TA	CCCTGCATG TCACAGCTT TA	no probe	N/A	N/A	60
TNF	CTCCACCCA TGTGCTCCT CA	CTCTGGCAG GGGCTCTTG AT	CACCATCAGCCG CATCGCCGTCTC	100	3	60
TLRI	AGCAAAGAA ATAGATTAC ACATCA	TTACCTACA TCATACACT CAAAT	ATTCCTCCTGTT GATATTGCTTTTG	60	5	57
TLR2	GCAAGCTGC GGAAGATAA TG	CGCAGCTCT CAGATTTAC CC	ATGGACGAGGCT CAGCGGGAAG	60	3	60
TLR4	ATGAAATGA GTTGCAGCA GA	AGCCATCTG TGTCTCCCT AA	AAGTGATGTTTG ATGGACCTCTGA ATCT	60	4	58
TLR6	TTTACTTGG ATGATGGTG AATAGT	AGTTCCCCA GATGAAACA TT	GTCGTAAGTAAC TGTCTGGAGGTGC	100	5	57
VCAM	CGAGACCAC CCCAGAATC TA	CTGTGGTGC TGCAAGTCA AT	no probe	N/A	N/A	60

antibody / ligand	amount per sample	order no.	supplier
FITC anti-human CD9, Mouse IgG1, kappa [HI9a 25]	0.5 µg	BLD-312103	Biozol
FITC anti-human CD63, Mouse IgG1, [H5C6]	1 µg	BLD-353005	Biozol
FITC Mouse IgG1, kappa Isotype Ctrl (FC) [MOPC-21]	1 µg	BLD-400109	Biozol
APC anti-human TLR2 (CD282) Mouse IgG2a [TL2.1]	2 µg	17-9922-41	ThermoFisher
APC Mouse IgG2a kappa Isotype Control [eBM2a]	2 µg	17-4724-81	ThermoFisher
Rhodamine-conjugated Pam ₃ CSK ₄	0.5 µg	tlrl-rpms	Invivogen

Supplementary Table 2: Antibodies and TLR2 ligands for flow cytometry.